Trombofilicheskie riski sovremennoy gormonal'noy kontratseptsii
- Authors: Pustotina O.A1
-
Affiliations:
- Issue: No 12 (2014)
- Pages: 12-15
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287135
- ID: 287135
Cite item
Abstract
The article presents the literature data on the impact of modern hormonal contraceptives on thrombophilic risk; a comparative characterization of various synthetic gestogens and estrogens in relation to the development of arterial and venous thrombosis is presented.
Keywords
Full Text
References
- US Selected Practice Recommendations for Contraceptive Use, 2013. http://www.cdc.gov/mmwr/pdf/rr/rr62e0614.pdf.
- WHO. Medical eligibility criteria for contraceptive use. Fouth edition, 2009. 125 p.
- Alkema L., Kantorova V., Menozzi C., Biddlecom A. National, regional, and global rates and trendsin contraceptive prevalence and unmet need for family planing between 1990 and 2015: a systematic and comprehensive analysis. Lanset. 2013; 381: 1642-51.
- Lopez L.M., Steiner M., Grimes D.A., et al. Strategies for communicating contraceptive effectiveness. Cochrane Database Syst. Rev. 2013; 4: CD006964.
- Lidegaard O. Hormonal contraception and venous thromboembolic risk in mid life women. Editorial. Maturitas. 2013; 74: 1-8.
- van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-controlstudy. BMJ. 2009; 339: b2921.
- FDA. Office of surveillance and epidemiology. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. 2011. www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf.
- WHO. Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial in farction and combined oral contraceptives: results of aninternational multicentrecase-control study. Lancet. 1997; 349: 1202-09.
- Lidegaard O., Lokkegaard E., Jensen A., et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N. Engl. J. Med. 2012; 366: 2257-66.
- Chan W.S., Ray J., Wai E.K., et al. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern. Med. 2004; 164: 741-47.
- Knopp R.H., LaRosa J.C., Burkman Jr R.T. Contraception and dyslipidemia. Am. J. Obstet. Gynecol. 1993: 168; 1994-2005.
- Lubianca J.N., Faccin C.S., Fuchs F.D. Oral contraceptives% a risk factor for uncontrolled blood pressure among hypertensive women. Contraception. 2003; 67: 19-24.
- Tepper N.K., Curtis K.M., Steenland M.W., Marchbanks P.A. Blood pressure measurement prior to initiating hormonal contraception: a systematic review. Contraception. 2013; 87: 631-40.
- Sherif K. Benefits and risks of oral contraceptives. Am. J. Obstet. Gynecol. 1999; 180(6Pt2): 343-48.
- WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of aninternational multicentrecase-controlstudy. Contraception. 1998; 57: 315-24.
- Sidneya S., Cheethamb T., Frederick A., et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2012; 87: 93-100.
- Raps M., Helmerhost F., Fleisher K., et al. Sexhormone-bindingglobulinas a marker for the thrombotic risk of hormonal contraceptives. J. Thromb. Haemost. 2012; 10(6): 992-97.
- Lidegaard O., Nielsen L.H., Skovlund C.W., Lokkegaard E. Venous thrombosis in users of nonoral hormonal contraception: follow-upstudy, Denmark, 2001-10, BMJ. 2012; 344: e2990.
- Parkin L., Sharples K., Hernandez R., Jick S. 2011. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011; 342: d2139.
- Lidegaard O., Nielsen L.H., Skovlund C.W., et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogendoses: Danishcohortstudy, 2001-9. BMJ. 2011; 343: d6423.
- Dinger J., Heinemann L., Khl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contrac. 2007; 75(5): 344-54.
- Heit J., Kobbervig C., James A., Petterson T., Bailey K., Melton L. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study. Ann intern Med. 2005; 143(10): 697-706.
- Manzoli L., Vito C., Marzuillo C., et al. Oral contraceptives and Venous Thromboembolism a systematic review and meta-analysis. Drug Saf. 2012; 35(3): 191-205.
- Dinger J., Assmann A., Möhner S., Minh T.D. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J. Fam. Plann. Reprod. Health Care. 2010; 36: 123-29.
- Kemmeren J.M., Algra A., Meijers J.C., et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood. 2004; 103: 927-33.
- Руководство по контрацепции / Под ред. В.Н. Прилепской. Изд. 2-е, перераб. и доп. М., 2010. 444 с.
- Royal College of General Practitioners: Oral contraceptives, venous thrombosis and varicose veins. J. R. Coll. Gen. Pract. 1978; 28: 393-99.
- Westhoff C., Kaunitz A.M., Korver T., et al. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrolacetate and 17β-estradiol: a randomized controlled trial. Obstet. Gynecol. 2012; 119: 989-99.
- Agren U.M., Anttila M., Maenpaa-Liukko K., et al. Effects of a monophasic combined oral contraceptive containing nomegestrolacetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur. J. Contracept. Reprod. Health. Care 2011; 16: 444-57.
- Jensen J.T. Evaluationof a new estradiol oral contraceptive: estradiol valerate and dieogest. Expert. Opin. Pharmacother. 2010; 11: 1147-57.
- Grow D.R. Metabolism of endogenous and exogenous reproductive hormones. Obstet. Gynecol. Clin. North Am. 2002; 29: 425-36.
- Gerstman B.B., Piper J.M., Tomita D.K., et al. Oral contraceptive estrogen dose and risk of deep venous thromboembolic disease. Am. J. Epidem. 1991; 133: 32-37.
- Vlieg A.V.H., Helmerhorst F.M., Vandenbroucke J.P., et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339: b2921.
- Sandset P.M., Hoibraaten E., Eilertsen A.L., Dahm A. Mechanism soft hrombosis related to hormone therapy. Thromb. Res. 2009; 123(2): 70-3.
- Odlind V., Milsom I., Persson I.,Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet. Gynecol. Scand. 2002; 81: 482-90.
- Fleischer K., vanVliet H.A., Rosendaal F.R., et al. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-overstudy. Thromb. Res. 2009; 123: 429-35.
- Johnson J.V., Lowell J., Badger G.J., et al. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet. Gynecol. 2008; 111: 278-84.
- Lidegaard O., Lokkegaard E., Svendsen A.L., Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-upstudy. BMJ. 2009; 339: b2890.
- Grimes D.A., Lopez L.M., O'Brien P.A., Raymond E.G. Progestin-only pills for contraception. Cochrane Database Syst. Rev. 2010; (1): CD007541.
- Baillargeon J.P., McClish D.K., Essah P.A., Nestler J.E. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin. Endocrinol. Metab. 2005; 90: 3863-70.
- van Hylckama Vlieg A., Helmerhorst F.M., Rosendaal F.R. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel in trauterine device. Arterioscler. Thromb. Vasc. Biol. 2010; 30: 2297-3000.
- Alexander N.J., Baker E., Kaptein M., et al. Why consider vaginal drug administration? Fertility Sterility. 2004; 82(1): 1-12.
- Brito M.B., Rui A., Ferriani J.C.M. Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: A randomized controlled trial. Thrombosis Res. 2012; 130: 355-60.